Incyte (INCY) Competitors $91.28 +1.97 (+2.21%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$91.81 +0.53 (+0.58%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ABBV, ALNY, REGN, BIIB, UTHR, NBIX, IONS, EXAS, EXEL, and BMRNShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include AbbVie (ABBV), Alnylam Pharmaceuticals (ALNY), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exact Sciences (EXAS), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector. Incyte vs. Its Competitors AbbVie Alnylam Pharmaceuticals Regeneron Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Ionis Pharmaceuticals Exact Sciences Exelixis BioMarin Pharmaceutical AbbVie (NYSE:ABBV) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership. Is ABBV or INCY more profitable? Incyte has a net margin of 18.99% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 699.66% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets AbbVie6.45% 699.66% 13.64% Incyte 18.99%21.99%14.43% Do insiders & institutionals have more ownership in ABBV or INCY? 70.2% of AbbVie shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 0.3% of AbbVie shares are owned by company insiders. Comparatively, 17.8% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, ABBV or INCY? AbbVie has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbVie$56.33B7.15$4.28B$2.10108.60Incyte$4.24B4.20$32.62M$4.4020.75 Which has more volatility & risk, ABBV or INCY? AbbVie has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Do analysts prefer ABBV or INCY? AbbVie currently has a consensus target price of $234.80, indicating a potential upside of 2.96%. Incyte has a consensus target price of $84.79, indicating a potential downside of 7.11%. Given AbbVie's stronger consensus rating and higher probable upside, research analysts clearly believe AbbVie is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 9 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.74Incyte 1 Sell rating(s) 12 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.32 Does the media prefer ABBV or INCY? In the previous week, AbbVie had 61 more articles in the media than Incyte. MarketBeat recorded 87 mentions for AbbVie and 26 mentions for Incyte. AbbVie's average media sentiment score of 1.02 beat Incyte's score of 0.86 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 57 Very Positive mention(s) 10 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 13 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive SummaryAbbVie beats Incyte on 11 of the 17 factors compared between the two stocks. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.82B$3.46B$6.21B$10.81BDividend YieldN/A2.28%5.72%4.80%P/E Ratio20.7528.5131.6030.98Price / Sales4.20497.40595.06133.64Price / Cash164.8846.9537.2561.86Price / Book5.1010.4012.056.61Net Income$32.62M-$52.83M$3.34B$277.10M7 Day Performance4.24%2.10%1.94%2.57%1 Month Performance10.37%10.17%6.88%3.20%1 Year Performance40.28%16.57%56.06%33.22% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.4853 of 5 stars$91.28+2.2%$84.79-7.1%+40.3%$17.82B$4.24B20.752,617Upcoming EarningsAnalyst ForecastABBVAbbVie4.5952 of 5 stars$230.36-0.1%$231.90+0.7%+21.4%$407.19B$56.33B109.7055,000Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionALNYAlnylam Pharmaceuticals4.0091 of 5 stars$464.95+1.0%$457.08-1.7%+62.7%$60.36B$2.25B-188.242,230Upcoming EarningsAnalyst ForecastREGNRegeneron Pharmaceuticals4.8858 of 5 stars$557.73-1.2%$817.88+46.6%-38.1%$59.84B$14.20B14.0615,106Positive NewsUpcoming EarningsAnalyst ForecastBIIBBiogen4.7242 of 5 stars$144.69-1.3%$180.15+24.5%-17.5%$21.49B$9.68B13.837,605Trending NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionUTHRUnited Therapeutics4.8436 of 5 stars$440.06+0.0%$457.21+3.9%+20.1%$19.85B$2.88B17.181,305Positive NewsUpcoming EarningsAnalyst ForecastInsider TradeNBIXNeurocrine Biosciences4.3186 of 5 stars$137.35+0.5%$163.44+19.0%+24.1%$13.55B$2.36B40.641,800Upcoming EarningsAnalyst ForecastIONSIonis Pharmaceuticals3.3029 of 5 stars$70.59+0.9%$78.28+10.9%+80.8%$11.15B$705M-38.361,069Upcoming EarningsAnalyst ForecastEXASExact Sciences4.5038 of 5 stars$59.36+1.7%$69.19+16.6%-6.5%$11.04B$2.76B-10.937,000Analyst ForecastEXELExelixis4.7564 of 5 stars$38.44+0.8%$44.42+15.6%+38.9%$10.27B$2.17B18.481,147Analyst UpgradeAnalyst RevisionBMRNBioMarin Pharmaceutical4.9843 of 5 stars$52.45+0.2%$93.26+77.8%-21.9%$10.05B$2.85B15.563,040News CoverageUpcoming EarningsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies AbbVie Competitors Alnylam Pharmaceuticals Competitors Regeneron Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors Ionis Pharmaceuticals Competitors Exact Sciences Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
